Browsing by Author "Goodenow MM"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    The case for an HIV cure and how to get there.
    (2021-Jan) Dybul M; Attoye T; Baptiste S; Cherutich P; Dabis F; Deeks SG; Dieffenbach C; Doehle B; Goodenow MM; Jiang A; Kemps D; Lewin SR; Lumpkin MM; Mathae L; McCune JM; Ndung'u T; Nsubuga M; Peay HL; Pottage J; Warren M; Sikazwe I; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Paris, France.; RTI International, Research Triangle Park, NC, USA.; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; Viiv Healthcare, Brentford, UK.; International Treatment Preparedness Coalition, Johannesburg, South Africa.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA. Electronic address: mrd54@georgetown.edu.; Sommartel, London, UK.; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; University College London, London, UK.; AIDS Vaccine Advocacy Coalition, New York, NY, USA.; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Joint Adherent Brothers & Sisters Against AIDS, Kampala, Uganda.; Kenya Ministry of Health, Nairobi, Kenya.; University of California, San Francisco, California, USA.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA.; Office of AIDS Research, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.